Insmed Incorporated (INSM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 8.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.96% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
- Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?
- INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
- Insmed stock falls as CFO Sara Bonstein to step down
- Insmed Announces CFO Transition
- Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative?
- FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
- The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Insmed Incorporated.
Full INSM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.